血清微小RNA(miR-129-3p、miR-767-3p和miR-877)在结直肠癌诊断中的价值

目的:探讨血清微小RNA (microRNA,mi RNA)在结直肠癌诊断中的价值.方法:通过miRNA表达谱芯片检测7例结直肠癌患者血清和10例健康志愿者血清中差异表达的miRNA.应用实时荧光定量PCR法在40例结直肠癌患者血清和18例健康志愿者血清中验证芯片结果,并分析血清特异性miRNA在结直肠癌诊断中的价值.结果:筛选获得10个在结直肠癌中特异性表达的血清miRNA,实时荧光定量PCR验证后获得一组结直肠癌特异性血清miRNA(miR-129-3p、miR-767-3p及miR-877*)生物标志物,这组生物标志物组合检测结直肠癌的灵敏度为77.78％、特异度为100％,并可产生最大受试者工作特征曲线(receiver operator characteristic curve,ROC)的曲线下面积(area under the curve,AUC)为0.914.结论:miR-129-3p、miR-767-3p和miR-877*生物标志物组合有望成为结直肠癌筛查和早期诊断的指标.     

结直肠癌相关成纤维细胞的microRNA的差异表达谱

目的:分析结直肠癌相关成纤维细胞(carcinoma associated fibroblasts,CAFs)与正常成纤维细胞(normal fibroblasts,NFs)的微小RNA(miRNA)表达谱差异。方法:收集结直肠癌组织和癌旁正常肠黏膜共3对,抽提、纯化RNA,加入荧光标记后与miRNA寡核苷酸基因芯片杂交,应用SAM软件进行数据分析,对有显著差异的miRNA进行实时荧光定量PCR验证,采用靶基因分析软件分析miRNA功能。结果:hsa-miR-138,hsa-miR-210,hsa-99a等12个miRNA在肿瘤组织中显著上调,中位假基因验出率(FDR)<5%;has-miR-29b、has-miR-494、has-miR-126等28个miRNA显著下调(FDR<5%)。结论:结直肠癌与正常结肠黏膜之间存在明显的miRNA差异表达谱,这些miRNA的差异性表达可能与结直肠癌的发病、侵袭、转移相关。     

血清miRNA作为结直肠癌患者诊断标志物的价值研究

[目的]探讨特征性血液miRNA作为结直肠癌诊断标志物的可行性.[方法]用miRNA的定量PCR芯片,从结直肠癌患者和健康对照者血清中筛选出候选的特征性miR-NA.再以线虫cel-39作为外参,采用相对定量法分析36例结直肠癌患者及25名健康对照者血清中候选miRNA表达情况.[结果]9条miRNA呈特征性表达,其中5条miRNA明显上调,4条明显下调;9条特征性表达的miRNA均得以验证.将9条特征性血清miRNA进行聚类分析,可见其能够清晰地将结直肠癌患者与健康对照者分为两类.采用ROC曲线分析发现被检测结直肠癌样本的曲线下面积(AUC)达0.934 (95％CI:0.877～0.992)(P＜0.001).[结论]miR-21等9条miRNA组合检测可作为结直肠癌诊断的生物标志物.     

miRNA-21及miRNA-375在新疆哈萨克族及维吾尔族食管癌早期诊断中的应用价值

目的 分析miRNA-21及miRNA-375在新疆哈萨克族及维吾尔族食管癌早期诊断中的应用价值.方法 收集60例新疆哈萨克族食管癌早期患者、60例新疆哈萨克族健康体检者、80例新疆维吾尔族食管癌早期患者、80例新疆维吾尔族健康体检者的血浆标本,采用荧光定量PCR法检测血清miRNA-21及miRNA-375的表达水平.结果 新疆哈萨克族和维吾尔族食管癌早期患者miRNA-21表达明显高于同族健康体检者,miRNA-375表达明显低于同族健康体检者,差异均有统计学意义(P﹤0.01).结论 新疆哈萨克族及维吾尔族食管癌早期患者中,miRNA-21表达明显升高,miRNA-375表达明显降低,可以作为临床诊断的重要标志.     

血浆外泌体miR-423-5p在前列腺癌骨转移患者中的差异表达分析

目的:研究血浆外泌体来源microRNA（miRNA）,作为前列腺癌骨转移的潜在标志物。方法:选取3例初诊为前列腺癌骨转移患者和3例局限性前列腺癌患者,收集患者外周静脉血10 mL,使用超速离心法及透射电子显微镜对血浆外泌体提取和鉴定。应用高通量测序分析血浆外泌体miRNA的差异表达谱。通过基因数据库GEO和已发表文章对差异miRNA筛选,选取测序结果中差异表达miRNAs,对7例局限性前列腺癌患者和10例前列腺癌骨转移患者的血浆外泌体进行qRT-PCR验证,同时结合GEO数据库样本进行验证。结果:高通量测序结果显示,从患者外周血浆外泌体中平均检测到740种miRNAs,通过R软件计算差异miRNA,得出61种差异miRNA;与对照组相比,hsa-miR-885-5p、hsa-miR-1255a、hsa-miR-122-5p、hsa-miR-141-3p、hsa-miR-423-5p、hsa-miR-1224-5p等在骨转移组中差异表达,通过靶基因功能及数据库表达选取miRNA进行PCR验证,发现hsa-miR-423-5p表达差异具有统计学意义（P=0.033）。通过数据库对60例局限性前列腺癌患者和40例骨转移患者统计发现,hsa-miR-423-5p在前列腺癌骨转移中显著下调（P=0.001<0.05）。结论:血浆外泌体来源miR-423-5p在前列腺癌骨转移中显著下调,有望成为前列腺癌骨转移患者中新的标志物。     

直肠腺癌组织中microRNA差异表达谱分析

目的 研究直肠癌及正常直肠黏膜中微小RNA（miRNA）表达谱差异,寻找并验证具有差异表达的miRNA。方法 提取3例直肠癌患者的癌组织及其对应远端正常直肠黏膜中的miRNA,采用微阵列芯片分析,获得直肠癌 miRNA表达谱。另取 15例直肠癌患者手术切除标本的癌组织及正常黏膜组织,采用实时定量RT-PCR法对其中具有表达差异的 hsa-miR-187*和hsa-miR-224进行进一步验证。结果 共筛选出70个直肠癌相关的差异表达miRNA,其中33个表达上调,37个表达下调。其中肿瘤/正常倍数小于0.5的有22个,肿瘤/正常倍数大于4的有17个。在另外15对验证样本中证实hsamiR-187*在直肠癌中表达下调（P<0.001）,hsa-miR-224表达上调（P<0.001）。结论 直肠癌和正常直肠黏膜相比有其特异的miRNA表达谱, miRNA在直肠癌的发生中可能起到重要作用。     

结直肠癌肝转移特定基因miRNA芯片甄别

目的:筛选结直肠癌(colorectal cancer,CRC)肝转移miRNA对应的特定基因。方法:收集10例CRC患者肿瘤组织标本,其中同时伴肝转移者5例,无远处器官转移5例。应用miRNA芯片方法对两组样本的miRNA表达差异情况进行研究,并通过实时定量RT-PCR对miRNA的芯片表达差异进行验证,再利用软件预测靶基因。结果:总RNA提取的质量分析显示,每份样品总RNA的A260/A280为2.11～2.15。电泳结果显示,每份样品的总RNA均有清晰的28S和18S条带,RNA完好无降解,质量符合miRNA芯片的质量要求。肝转移组较非转移组筛选出6种CRC表达失调的miRNA,其中上调的为miR-224、miR-1236和miR-622,下调的为miR-155、miR-342-5p和miR-363,miR-224的差异信号值最高(>500)。芯片实验显示,hsa-miR-224在肝转移组呈现显著性上调,P=0.038 2;而hsa-miR-155在肝转移组却呈现显著性下调,P=0.043 2。miR-224的表达倍数在肝转移CRC组织中较非转移组表达上调(Fold change=2.47),P=0.016 6。结论:可调控CRC肝转移的特定基因miR-224的筛选,可作为早期诊断治疗的新手段。     

结直肠癌患者外周血CRD-BP RNA表达的探索性研究

目的:本研究通过检测结直肠癌患者外周血中CRD-BP RNA的表达情况,探讨结直肠癌患者外周血中CRD-BPRNA的表达情况与患者临床特性的相关性.方法:应用荧光定量巢式逆转录聚合酶链反应方法检测32例结直肠癌患者和35例对照组人群外周血中CRD-BP RNA的表达.结果:结直肠癌组32个样本中有10个样本检测到CRD-BP RNA表达,阳性表达率为31.25%,对照组35个样本均未检测到CRD-BPRNA表达,两组间差异有统计学意义(P＜0.05);实验组中CRD-BP RNA的表达与临床分期及有无淋巴结转移密切相关,各组间比较有统计学意义(P＜0.05).结论:外周血中检测CRD-BP RNA可能会成为结直肠癌的肿瘤标志物并用于诊断;结直肠癌患者外周血中CRD-BP RNA表达可能与临床分期相关.     

miR-338基因簇与食管癌发病风险的病例对照研究

目的: 探讨miR-338基因簇在食管癌组织中的表达模式及其与食管癌发病风险的关系。方法: 选取86例经病理确诊的食管癌患者,分别提取食管癌和癌旁组织总RNA,采用实时荧光定量PCR法检测hsa-miR-338-3p、hsa-miR-338-5p与hsa-miR-657的表达,应用配对样本t检验分析癌和癌旁组织中miRNA表达差异,Pearson相关分析检验基因簇各miRNA表达的相关性,logistic回归分析miRNA异常表达对食管癌发病风险的影响。结果: hsa-miR-338-3p与hsa-miR-338-5p在食管癌组织中的表达均较癌旁组织降低(P均<0.05),hsa-miR-657在食管癌和癌旁组织中表达的差异无统计学意义(P>0.05),hsa-miR-338-3p与hsa-miR-338-5p表达显著相关(r=0.754,P<0.05),hsa-miR-338-5p的低表达增加了食管癌的发病风险(OR=1.264,P<0.05),可能是食管癌的危险因素。结论: miR-338基因簇可能抑制了食管癌的发生,hsa-miR-338-5p可能成为食管癌诊断的潜在标志物。     

人支气管上皮hsa-miR-148a-3p 低表达细胞株的建立

目的： 建立稳定的hsa-miR-148a-3p低表达人支气管上皮细胞株(16HBE)。方法：根据miRBase中提供的序列信息设计hsa-miR-148a-3p tough decoy RNA(TuD RNA),并将其连接到慢病毒载体pLKO.1-puro上。将重组慢病毒载体转染至293FT细胞并包装为慢病毒后,收集病毒上清,感染正常16HBE细胞。用嘌呤霉素筛选出has-miR-148a-3p低表达的16HBE细胞株,通过荧光定量PCR对其进行鉴定,然后对筛选出的细胞分别采用荧光定量PCR和Western blot检测DNA甲基转移酶1(DNMT1) mRNA和蛋白的表达水平。结果：测序结果表明含hsa-miR-148a-3p TuD RNA的重组慢病毒载体构建成功;荧光定量PCR检测显示has-miR-148a-3p低表达的16HBE细胞株has-miR-148a-3p的表达量比正常16HBE细胞低44%(P<0.01),其作用靶基因DNMT1的mRNA和蛋白表达水平分别为正常细胞的3.4倍和2.0倍(P均<0.01)。结论：成功建立hsa-miR-148a-3p低表达的16HBE细胞,hsa-miR-148a-3p的低表达能提高DNMT1 mRNA和蛋白的表达水平。     

The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma

BackgroundThe aberrant expression of microRNAs (miRNAs) is associated with a variety of diseases including cancers. In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.MethodsWe screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR. The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples. The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan–Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.ResultsAfter a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples. Unsupervised clustering analysis further revealed the great potential of the 7-miRNA profile to differentiate between tumours and normal brain tissues. The down-regulation of hsa-miR-137 in astrocytomas was shown to be associated with advanced clinical stages of this disease. Using Kaplan–Meier survival analysis we showed that low expression of hsa-miR-181b or hsa-miR-106a, or high expression of hsa-miR-21 was significantly associated with poor patient survival. Moreover, Cox proportional hazard regression analysis revealed that this prognostic impact was independent of other clinicopathological factors.ConclusionsOur results suggest a great potential for the use of miRNA profiling as a powerful diagnostic and prognostic marker in defining the signature of astrocytomas and in predicting the post-surgical outcome.     

Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma

Prostate cancer (PCa) has become a prevalent malignant disease in males globally. Accumulating data suggested that hsa-microRNAs (miRNAs) could be potential biomarkers for tumor diagnosis due to their important roles in the cell cycle. This study investigated the diagnostic and prognostic values of hsa-miR-203 and hsa-miR-30c in PCa tissues. There were 44 pathologically confirmed PCa patients who were enrolled in this study. Tissue samples were collected from both tumor tissues and adjacent normal tissues. RNA was extracted and the expression levels of hsa-miR-203 and hsa-miR-30c in tumor and normal tissues were compared. The receiver operating characteristic (ROC) curves were plotted to evaluate the reliability of hsa-miR-203 and hsa-miR-30c in detecting PCa. All subjects in this study were followed up by 36 months, and the Kaplan-Meier method was conducted to investigate the survival status of PCa patients. The average relative expressions of hsa-miR-203 and hsa-miR-30c in tumor tissues were significantly different from those in adjacent normal tissues (P?<?0.001), and the predictive power of the two hsa-miRNAs for PCa prognosis was reliable. Besides that, the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of PCa.     

Serum levels of hsa-miR-16-5p,hsa-miR-29a-3p,hsa-miR-150-5p,hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25–p75: 7–13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR_{1∆Ct-unit increase} (95%CI) = 1.42 (1.18–1.72), 1.64 (1.31–2.04) and 1.75 (1.31–2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve <0.62). hsa-miR-16-5p and hsa-miR-223-3p levels were unrelated to CLL risk. The findings of this first prospective study suggest that hsa-miR-29a, hsa-miR-150-5p and hsa-miR-155-5p were upregulated in early stages of CLL but were modest predictive biomarkers of CLL risk.     

Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk

To explore the associations of SNPs within hsa-miR-605 (rs2043556) and hsa-miR-149 (rs2292832) and lifestyle-related factors with gastrointestinal cancer, a case-control study including 762 cases and 757 controls was conducted. Marginally significant associations were found both for hsa-miR-149 rs2292832 with gastric cancer risk (TC?+?CC vs. TT, OR?=?0.68, 95% CI: 0.44-1.04) and for hsa-miR-605 rs2043556 with colorectal cancer risk (AG?+?GG vs. AA, OR?=?0.70, 95% CI: 0.48-1.02) in males. Tea drinking showed a protective effect on gastric cancer risk (OR?=?0.28, 95% CI: 0.13-0.60), while smoke inhalation increased the risk of gastric cancer (OR?=?1.94, 95% CI: 1.08-3.47). Irritability was found to be a risk factor for both colorectal cancer (OR?=?1.61, 95% CI: 1.02-2.53) and gastric cancer (OR?=?1.96, 95% CI: 1.17-3.29). Among those that engaged in smoke inhalation, miR-149 CT/CC and miR-605 AG/GG genotype carriers had increased susceptibilities to colorectal cancer (OR?=?1.90, 95% CI: 1.11-3.25) and gastric cancer (OR?=?1.87, 95% CI: 1.03-3.42), respectively. Among the tea drinkers, there exists a marginally protective effect of miR-605 AG/GG genotypes on colorectal cancer incidence (OR?=?0.71, 95% CI: 0.47-1.06) and a significantly protective effect of miR-149 CT/CC on gastric cancer incidence (OR?=?0.47, 95% CI: 0.29-0.77). The SNPs of rs2292832 and rs2043556 might be able to modify the susceptibility to male gastric and colorectal cancers, respectively. Tea drinking is a protective factor, while smoke inhalation is a risk factor for gastric cancer, and they might have the potential to modify the associations between miR-149 and miR-605 polymorphisms with gastrointestinal cancer risk. In addition, irritability was shown to be a risk factor for both gastric and colorectal cancers. ? 2011 Wiley Periodicals, Inc.     

Hypomethylation of the hsa-miR-191 Locus Causes High Expression of hsa-miR-191 and Promotes the Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma

hsa-miR-191 is highly expressed in hepatocellular carcinoma (HCC), but the factors regulating this elevated expression are unknown. This study aimed to investigate the epigenetic mechanisms of increased hsa-miR-191 expression by analyzing the relationship between the DNA methylation status of hsa-miR-191 and miR-191 expression. Methylation-specific polymerase chain reaction (PCR), bisulfite sequencing PCR, Northern blot, and quantitative real-time PCR were performed to examine hsa-miR-191 methylation and expression levels. Western blot, transwell, and scratch assays were performed to examine the function and molecular mechanisms of hsa-miR-191. Approximately 58.9% of hsa-miR-191 expression was higher in HCC tissues than in adjacent noncancerous tissues; this high expression was associated with poor prognosis. The hypomethylation observed in some HCC cell lines and HCC tissues was correlated with the hsa-miR-191 expression level. This correlation was validated by treatment with the 5-aza-DAC demethylation agent. The level of hypomethylation was 63.0% in 73 clinical HCC tissue samples and was associated with increased (2.1-fold) hsa-miR-191 expression. The elevated expression of hsa-miR-191 in the SMMC-771 HCC cell line induced the cells to transition into mesenchymal-like cells; they exhibited characteristics such as loss of adhesion, down-regulation of epithelial cell markers, up-regulation of mesenchymal cell markers, and increased cell migration and invasion. Inhibiting hsa-miR-191 expression in the SMMC-7721 cell line reversed this process (as assessed by cell morphology and cell markers). Furthermore, hsa-miR-191 probably exerted its function by directly targeting TIMP metallopeptidase inhibitor 3 and inhibiting TIMP3 protein expression. Our results suggest that hsa-miR-191 locus hypomethylation causes an increase in hsa-miR-191 expression in HCC clinical tissues and that this expression induces HCC cells to transition into mesenchymal-like cells.     

Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection

BackgroundRecurrence is a major factor leading to treatment failure and death in gastric cancer (GC) patients following surgical resection. Importantly, the prediction of recurrence is critical in improving clinical outcomes. We isolated a group of microRNAs (miRNAs) and evaluated their usefulness as prognostic markers for the recurrence of GC.Patients and methodsA total of 65 GC patients were selected for systematic analysis, 29 patients with recurrence and 36 patients without recurrence. Firstly, miRNAs microarray and bioinformatics methods were used to characterize classifiers from primary tumor samples (n = 8). Following, we validated these predictors both in frozen fresh and paraffin-embedded tissue samples (n = 57) using quantitative PCR.ResultsWe have identified 17 differential miRNAs including 10 up-regulated and 7 down-regulated miRNAs in recurrence group. Using k-top scoring pairs (k-TSP) method, we further ascertained hsa-miR-375 and hsa-miR-142-5p as a classifier to recognize recurrence and nonrecurrence cases both in the training and test samples. Moreover, we validated this classifier in 34 frozen fresh tissues and 38 paraffin-embedded tissues with consistent sensitivity and specificity with training set; among them, 15 cases were matched. A high frequency recurrence and poor survival were observed in GC cases with high level of hsa-miR-375 and low level of hsa-miR-142-5p (P < 0.001). In addition, we evaluated that hsa-miR-375 and hsa-miR-142-5p were involved in regulating target genes in several oncogenic signal pathways, such as TP53, MAPK, Wnt and vascular endothelial growth factor.ConclusionOur results indicate that the combination of hsa-miR-375 and hsa-miR-142-5p as a predictor of disease progression has the potential to predict recurrence risk for GC patients.     

hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is generally a fatal disease due to a paucity of effective treatment options. The identification of oncogenic microRNAs that exert pleiotropic effects in HCC cells may offer new therapeutic targets. In this study, we have identified the human microRNA miR-191 as a potential target for HCC therapy. Inhibition of miR-191 decreased cell proliferation and induced apoptosis in vitro and significantly reduced tumor masses in vivo in an orthotopic xenograft mouse model of HCC. Additionally, miR-191 was found to be upregulated by a dioxin, a known liver carcinogen, and was found to be a regulator of a variety of cancer-related pathways. Our findings offer a preclinical proof of concept for miR-191 targeting as a rational strategy to pursue for improving HCC treatment.     

hsa-miR-23a-3p在肺腺癌组织中的表达及意义

[目的]探讨hsa-miR-23a-3p在肺腺癌织中的表达水平及临床意义。[方法]收集我院呼吸科就诊的42例肺腺癌患者的癌组织及癌旁组织样本,同时选取37例非肺腺癌患者的肺穿刺样本为对照组。采用荧光定量PCR法检测各组患者肺组织中hsa-miR-23a-3p相对表达水平,分析hsa-miR-23a-3p在肺腺癌组织中的表达及与患者临床特征的关系;以患者血清癌胚抗原(CEA)指标为参考,利用受试者工作特征曲线(ROC)评估肺腺癌患者癌组织中hsa-miR-23a-3的表达临床应用价值。[结果]对照组与癌旁组织中hsa-miR-23a-3p的表达水平差异无统计学意义(4.32±0.34 vs 4.16±0.41,P>0.05),与对照组与癌旁组织比,肺腺癌组织hsa-miR-23a-3p表达较高(6.08±0.47 vs 4.32±0.34,6.08±0.47 vs 4.16±0.41,P<0.01)。不同性别(6.16±0.82 vs 5.89±0.73)、分化程度(6.20±0.84 vs 5.97±0.67)癌组织的hsa-miR-23a-3p表达差异无统计学意义(P>0.05),TNM分期越高(5.13±0.49 vs 6.26±0.51)、肿瘤越大(6.47±0.65 vs 5.94±0.71)、淋巴结转移(6.32±0.53 vs 5.83±0.46)及CEA阳性(6.47±0.44 vs 5.79±0.41)癌组织的hsa-miR-23a-3p表达显著性增高(P<0.001)。ROC曲线分析显示,与CEA比,hsa-miR-23a-3p的曲线下面积高(0.779vs 0.683)。[结论]肺腺癌组织hsa-miR-23a-3p呈高表达,与淋巴结转移、肿瘤大小及TNM分期相关,可用于辅助诊断肺腺癌。     

Analysis of hsa-miR-30a-5p Expression in Human Gliomas

Our previous study demonstrated that miR-30a-5p was upregulated in six malignant glioma cell lines by microRNA(miRNA) array. For further verification of this finding, the expression of miR-30a-5p in 7 more malignant glioma cell lines, 43 freshly resected glioma samples and 75 archival paraffin embedded glioma specimens with different grade of malignancy were examined by qRT-PCR and in situ hybridization(ISH). Here, we present the first evidence that miR-30a-5p is overexpressed in glioma cell lines and glioma samples as compared to the normal brain tissues (NBTs), and its expression level is positively correlated with tumor grade of malignancy. It is concluded that miR-30a-5p may have the potential as a diagnostic or prognostic marker of gliomas and as the target of miRNA-based glioma therapy in further studies.